Trial Profile
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Pasireotide (Primary) ; Insulin; Liraglutide; Metformin; Sitagliptin
- Indications Acromegaly; Pituitary ACTH hypersecretion
- Focus Therapeutic Use
- Sponsors Novartis Healthcare; Novartis Pharmaceuticals
- 18 Jun 2023 Post-hoc analysis results presented at the 105th Annual Meeting of the Endocrine Society
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 19 Jul 2018 Status changed from recruiting to completed.